Evidence map›Paper›PMID 29103145›Full record

ArticleNeuroradiology2018

Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy.

Luke A Perry, Panagiotis Korfiatis, Jay P Agrawal, Bradley J Erickson

Abstract read
PubMed Publisher
In one paragraph

Article in Neuroradiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Luke A PerryMonash University, Melbourne, Australia.
Panagiotis KorfiatisDepartment of Radiology, Mayo Clinic Rochester, 200 First St Sw, Rochester, MN, 55905, USA.
Jay P AgrawalDepartment of Radiology, University of Massachusetts Medical School, Worcester, MA, USA.
Bradley J EricksonDepartment of Radiology, Mayo Clinic Rochester, 200 First St Sw, Rochester, MN, 55905, USA. bje@mayo.edu.
Mayo Clinic · USMonash University · AUUniversity of Massachusetts Chan Medical School · US

Funding

Objective decision support environment for clinical trialsU01CA160045 · NCI · MAYO CLINIC ROCHESTER · PI ERICKSON, BRADLEY J. · 2012 to 2016
$2.6M
National Cancer Institute CA160045
6 · The paper itself

Abstract

purposeOur study tested the diagnostic accuracy of increased signal intensity (SI) within FLAIR MR images of resection cavities in differentiating early progressive disease (ePD) from pseudoprogression (PsP) in patients with glioblastoma treated with radiotherapy with concomitant temozolomide therapy.

methodsIn this retrospective study approved by our Institutional Review Board, we evaluated the records of 122 consecutive patients with partially or totally resected glioblastoma. Region of interest (ROI) analysis assessed 33 MR examinations from 11 subjects with histologically confirmed ePD and 37 MR examinations from 14 subjects with PsP (5 histologically confirmed, 9 clinically diagnosed). After applying an N4 bias correction algorithm to remove B0 field distortion and to standardize image intensities and then normalizing the intensities based on an ROI of uninvolved white matter from the contralateral hemisphere, the mean intensities of the ROI from within the resection cavities were calculated. Measures of diagnostic performance were calculated from the receiver operating characteristic (ROC) curve using the threshold intensity that maximized differentiation. Subgroup analysis explored differences between the patients with biopsy-confirmed disease.

resultsAt an optimal threshold intensity of 2.9, the area under the ROC curve (AUROC) for FLAIR to differentiate ePD from PsP was 0.79 (95% confidence interval 0.686-0.873) with a sensitivity of 0.818 and specificity of 0.694. The AUROC increased to 0.86 when only the patients with biopsy-confirmed PsP were considered.

conclusionsIncreased SI within the resection cavity of FLAIR images is not a highly specific sign of ePD in glioblastoma patients treated with the Stupp protocol.

Indexed as

Antineoplastic Agents, AlkylatingBrain NeoplasmsCombined Modality TherapyDacarbazineDisease ProgressionFemaleGlioblastomaHumansMagnetic Resonance ImagingMaleMiddle AgedRetrospective StudiesSensitivity and SpecificityTemozolomideAntineoplastic Agents, AlkylatingDacarbazineTemozolomideGlioblastomaMRIPseudoprogression

Identifiers

PMID29103145
OpenAlexW2766697779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.